Selected Mesothelioma Patients May Benefit From New Medical Treatment With Brentuximab Vedotin, An Antibody–Drug

On the Molecular Cancer Therapeutics medical journal website we found this encouraging article about a new mesothelioma treatment, “CD30 Is a Potential Therapeutic Target in Malignant Mesothelioma”.

From the Abstract from this early-online February 2015 medical journal article, which is relatively “technical”, we get this specific information about the most recent development in mesothelioma therapy:

CD30 is a cytokine receptor belonging to the TNF superfamily (TNFRSF8) that acts as a regulator of apoptosis….  There have been sporadic reports of CD30 expression in nonlymphoid tumors, including malignant mesothelioma. Given the remarkable success of brentuximab vedotin, an antibody–drug conjugate directed against CD30 antigen, in lymphoid malignancies, we undertook a study to examine the incidence of CD30 in mesothelioma and to investigate the ability to target CD30 antigen in mesothelioma….  Our studies validate the presence of CD30 antigen in a subgroup of epithelial-type mesothelioma tumors and indicate that selected mesothelioma patients may derive benefit from brentuximab vedotin treatment.

While our newly discovered treatment for mesothelioma may be limited to only certain patients, any advancement in caring for patients with this asbestos-related cancer is welcomed news.


 Mesothelioma, Asbestos, and Legal Compensation: Basic Facts

Asbestos-Mesothelioma Case Evaluation Form
Free.  Confidential.  No Obligation.

Speak Your Mind

*

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, NC 28403
Tel: (800) 426-9535
Email@LambLawOffice.com
Disclaimer and Copyright